Therapeutic efficacy of humanized anti-IL-6-receptor antibody in systemic juvenile idiopathic arthritis.

被引：0
|
作者：
Yokota, S
Miyamae, T
Imagawa, T
Nishimoto, N
Yoshizaki, K
Hirsch, R
Mori, M
机构：
来源：
ARTHRITIS AND RHEUMATISM | 2001年 / 44卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1432
引用
收藏
页码：S291 / S291
页数：1
相关论文
共 50 条
  • [31] The recombinant humanized anti-IL-6 receptor antibody tocilizumab, an innovative drug for the treatment of rheumatoid arthritis
    Ohsugi, Yoshiyuki
    Kishimoto, Tadamitsu
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2008, 8 (05) : 669 - 681
  • [32] Clinical trials for the treatment of systemic onset juvenile rheumatoid arthritis-juvenile idiopathic arthritis.
    Lehman T.J.
    Current Rheumatology Reports, 2000, 2 (4) : 313 - 315
  • [33] Interleukin 6 as a therapeutic target in systemic-onset juvenile idiopathic arthritis
    Yokota, S
    CURRENT OPINION IN RHEUMATOLOGY, 2003, 15 (05) : 581 - 586
  • [34] IL-6 Signaling and its Blockade with a Humanized Anti-Interleukin-6 Receptor Antibody in Rheumatoid Arthritis: Advent of a New and Innovative Therapeutic Drug, Tocilizumab
    Ohsugi, Yoshiyuki
    Kishimoto, Tadamitsu
    CURRENT RHEUMATOLOGY REVIEWS, 2011, 7 (04) : 288 - 300
  • [35] Interleukin-18 promoter polymorphisms in systemic juvenile idiopathic arthritis.
    D'Urbano, LE
    Muratori, F
    Cortis, E
    Insalaco, A
    de Benedetti, F
    Ugazio, AG
    ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : S364 - S365
  • [36] Tocilizumab (humanized anti IL-6 receptor monoclonal antibody) in patients with systemic lupus erythematosus (SLE): Safety, tolerability and preliminary efficacy.
    Illei, Gabor G.
    Yarboro, Cheryl
    Shirota, Yuko
    Tackey, Edward
    Lapteva, Larissa
    Fleisher, Thomas
    Balow, James
    Lipsky, Peter
    ARTHRITIS AND RHEUMATISM, 2006, 54 (12): : 4043 - 4043
  • [37] TOCILIZUMAB THERAPY IN CHILDREN WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS. RUSSIAN EXPERIENCE
    Alekseeva, E.
    Denisova, R.
    Valieva, S.
    Bzarova, T.
    Isayeva, K.
    Sleptsova, T.
    Mitenko, E.
    Chistyakova, E.
    Fetisova, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 736 - 737
  • [38] A multi-center, randomized, double blind, placebo-controlled study of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in children with systemic juvenile idiopathic arthritis
    Yokota, S.
    Imagawa, T.
    Mori, M.
    Takei, S.
    Kawano, Y.
    Iwata, N.
    Tomiita, M.
    Miyosh, M.
    Aihara, Y.
    Murata, T.
    Abukawa, D.
    Nishimoto, N.
    Kishimoto, T.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 59 - 60
  • [39] Therapeutic options in juvenile idiopathic arthritis. Part 1: Nonsurgical treatment
    Haas, J. -P.
    Arbogast, M.
    ORTHOPADE, 2018, 47 (11): : 912 - 918
  • [40] Juvenile idiopathic arthritis. Part 2: prognosis and current therapeutic approach
    Espada, Graciela
    ARCHIVOS ARGENTINOS DE PEDIATRIA, 2009, 107 (06): : 536 - 541
12345